CA3222934A1 - Antibodies which bind human fibrin or fibrinogen yc domain and methods of use - Google Patents
Antibodies which bind human fibrin or fibrinogen yc domain and methods of use Download PDFInfo
- Publication number
- CA3222934A1 CA3222934A1 CA3222934A CA3222934A CA3222934A1 CA 3222934 A1 CA3222934 A1 CA 3222934A1 CA 3222934 A CA3222934 A CA 3222934A CA 3222934 A CA3222934 A CA 3222934A CA 3222934 A1 CA3222934 A1 CA 3222934A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- cdr
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212409P | 2021-06-18 | 2021-06-18 | |
| US63/212,409 | 2021-06-18 | ||
| PCT/US2022/034188 WO2022266539A2 (en) | 2021-06-18 | 2022-06-20 | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222934A1 true CA3222934A1 (en) | 2022-12-22 |
Family
ID=84526539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222934A Pending CA3222934A1 (en) | 2021-06-18 | 2022-06-20 | Antibodies which bind human fibrin or fibrinogen yc domain and methods of use |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240279357A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355772A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024522237A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022293581A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222934A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022266539A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751301A2 (en) * | 2004-05-07 | 2007-02-14 | The Regents of the University of California, Office of the President | Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment |
| LT2483416T (lt) * | 2009-10-02 | 2017-04-25 | The Regents Of The University Of California | Monokloniniai antikūnai |
| DK2935331T3 (en) * | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| JP6907229B2 (ja) * | 2016-04-18 | 2021-07-21 | ファロン ファーマシューティカルズ オサケ ユキチュア | ヒト化抗clever−1抗体およびその使用 |
| PL3830119T3 (pl) * | 2018-08-01 | 2026-05-25 | Imcheck Therapeutics | Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych |
-
2022
- 2022-06-20 JP JP2023577931A patent/JP2024522237A/ja active Pending
- 2022-06-20 WO PCT/US2022/034188 patent/WO2022266539A2/en not_active Ceased
- 2022-06-20 EP EP22825965.1A patent/EP4355772A4/en active Pending
- 2022-06-20 US US18/571,091 patent/US20240279357A1/en active Pending
- 2022-06-20 CA CA3222934A patent/CA3222934A1/en active Pending
- 2022-06-20 AU AU2022293581A patent/AU2022293581A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240279357A1 (en) | 2024-08-22 |
| WO2022266539A2 (en) | 2022-12-22 |
| WO2022266539A3 (en) | 2023-01-26 |
| EP4355772A4 (en) | 2025-07-30 |
| AU2022293581A1 (en) | 2024-01-25 |
| EP4355772A2 (en) | 2024-04-24 |
| WO2022266539A9 (en) | 2023-09-14 |
| JP2024522237A (ja) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12358979B2 (en) | Antibodies that bind interleukin 13 and methods of use | |
| US20240279321A1 (en) | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE | |
| WO2024173847A2 (en) | Antibodies that bind interleukin 4 receptor alpha and methods of use | |
| US20240279357A1 (en) | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE | |
| CA3132185A1 (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| EP4705347A2 (en) | Antibodies that bind ox40l and methods of use | |
| WO2022159776A1 (en) | Antibodies which bind human fibrin and methods of use | |
| WO2025265071A1 (en) | Antibodies that bind tslp and methods of use | |
| US20260109756A1 (en) | Multi-specific antigen binding proteins which bind human fibrin or fibrinogen yc domain and vascular endothelial growth factor and methods of use | |
| WO2024076993A2 (en) | Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use | |
| WO2025212751A1 (en) | Multi-specific antigen-binding proteins which bind human fibrin yc or fibrinogen yc domain and vascular endothelial growth factor and methods of use | |
| WO2026085202A1 (en) | Antibodies that bind tslp and methods of use | |
| WO2026060117A1 (en) | Bispecific antibodies binding to tl1a and osmr | |
| EA052830B1 (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ДОМЕН γC ФИБРИНА ИЛИ ФИБРИНОГЕНА ЧЕЛОВЕКА, И СПОСОБЫ ПРИМЕНЕНИЯ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250613 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250613 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20251015 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260619 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260619 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260619 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260619 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260723 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260723 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260723 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260723 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260723 |